Adversarial Injection · Necitumumab (Portrazza; IMC-11F8; CAS 906805-06-9; MW ~148 kDa fully human IgG1κ; IV infusion 800 mg flat D1+D8 of 21-day cycle; anti-EGFR [HER1; ERBB1; chromosome 7p11.2; 1210-AA ~170 kDa; DOMAIN III competitive antagonist; EGF-binding groove; KD ~1.0 nM; PREVENTS EGF + TGF-α BINDING → NO EGFR TYROSINE KINASE ACTIVATION → NO RAS/ERK + NO PI3K/AKT]; IgG1κ ISOTYPE: FcγRIIIa CD16A ADCC RETAINED (DISTINCT FROM PANITUMUMAB IgG2 NO-ADCC); C1q CDC RETAINED; FULLY HUMAN (IMC-11F8 CLONE; IMCLONE SYSTEMS PHAGE-DISPLAY FULLY HUMAN ANTIBODY LIBRARY; NO MURINE SEQUENCES; NO HUMANIZATION REQUIRED); FIRST FULLY HUMAN ANTI-EGFR IgG1κ ANTIBODY EVER FDA APPROVED; SQUAMOUS NSCLC-SPECIFIC INDICATION (NOT NON-SQUAMOUS — INSPIRE TRIAL NEGATIVE: NECITUMUMAB + PEMETREXED/CISPLATIN NON-SQUAMOUS → NO BENEFIT + EXCESS VTE [THROMBOEMBOLIC EVENTS]); SQUIRE TRIAL (THATCHER NEJM 2015): NECITUMUMAB + GC [GEMCITABINE 1250 mg/m² D1+D8 + CISPLATIN 75 mg/m² D1; Q3W × ≤6 CYCLES] VS GC ALONE; 1L SQUAMOUS NSCLC; mOS 11.5 VS 9.9 MO (HR 0.84; 95%CI 0.74–0.96; p=0.0129); mPFS 5.7 VS 5.5 MO (HR 0.85; p=0.0205); ELI LILLY AND COMPANY INDIANAPOLIS IN + IMCLONE SYSTEMS [ACQUIRED $6.5B 2008]; NIOSH HD Category 1; CAS 906805-06-9 → NULL ALL EHS DATABASES) · Attack #752

Necitumumab (Anti-EGFR Fully Human IgG1κ MAb; Portrazza; IMC-11F8; CAS 906805-06-9; Eli Lilly and Company [Indianapolis IN; BLA 125463 holder; Portrazza developer; acquired ImClone Systems $6.5B 2008]; MECHANISM: FIRST EGFR [HER1; ERBB1; EGF RECEPTOR; CHROMOSOME 7p11.2; TYPE I RTK; DOMAIN III (EGF-binding groove; AA287–333; competitive antagonism; KD ~1.0 nM; prevents EGF/TGF-α/AR/epiregulin binding)] DIRECTED FULLY HUMAN IgG1κ (via IMCLONE SYSTEMS PHAGE-DISPLAY FULLY HUMAN ANTIBODY LIBRARY [human scFv phage library → IMC-11F8 clone → IgG1κ format; NO MURINE SEQUENCES; NO HUMANIZATION; FULLY HUMAN IgG1κ DISTINCT FROM CETUXIMAB CHIMERIC IgG1 AND PANITUMUMAB FULLY HUMAN IgG2]) ANTIBODY EVER FDA APPROVED FOR SQUAMOUS NSCLC + FIRST FULLY HUMAN ANTI-EGFR IgG1κ ANTIBODY EVER (IgG1 RETAINS ADCC VIA FcγRIIIa + CDC VIA C1q; DISTINCT FROM PANITUMUMAB IgG2 NO-ADCC; SHARES ADCC MECHANISM WITH CETUXIMAB BUT NO MURINE SEQUENCES → NO α-GAL IgE SENSITIZATION INFUSION REACTION; NO SQUAMOUS-HISTOLOGY-INDEPENDENT EFFICACY [INSPIRE NEGATIVE IN NON-SQUAMOUS → SQUAMOUS-HISTOLOGY SELECTION ESSENTIAL]); SQUIRE (THATCHER NEJM 2015): NECITUMUMAB + GEMCITABINE/CISPLATIN [GC] VS GC ALONE; 1L SQUAMOUS NSCLC; mOS 11.5 VS 9.9 MO [HR 0.84; p=0.0129]; BLA 125463 NOVEMBER 24 2015) — Eli Lilly and Company Indianapolis IN (BLA 125463 holder; Portrazza developer via ImClone acquisition), Boehringer Ingelheim Pharma GmbH Biberach Germany (Portrazza manufacturing partner; mAb production), and Dana-Farber Cancer Institute Boston MA (clinical squamous NSCLC treatment; Portrazza IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST FULLY HUMAN EGFR IgG1 ANTIBODY EVER + FIRST EGFR ANTIBODY FOR SQUAMOUS NSCLC EVER: AI Prompt Injection via EHS Monitor Report AI

Necitumumab (CAS 906805-06-9; NIOSH HD Category 1) is the first fully human IgG1κ anti-EGFR (HER1; ERBB1) monoclonal antibody ever FDA approved for squamous non-small-cell lung cancer, establishing the 168th mechanism class in the Glyphward adversarial portfolio. Developed by ImClone Systems from a phage-display fully human antibody library (clone IMC-11F8 selected for EGFR domain III binding; KD ~1.0 nM), necitumumab (Portrazza) achieves EGFR competitive antagonism with an IgG1κ framework — retaining ADCC (FcγRIIIa) and CDC (C1q) effector mechanisms absent in panitumumab (IgG2), while having no murine sequences (eliminating α-Gal IgE-mediated infusion reactions seen with cetuximab). The squamous NSCLC-specific indication (SQUIRE trial: mOS 11.5 vs 9.9 months; HR 0.84; p=0.0129 for necitumumab + gemcitabine/cisplatin vs GC alone) reflects histology-dependent efficacy — the companion INSPIRE trial (non-squamous NSCLC + pemetrexed/cisplatin) showed no PFS/OS benefit and excess thromboembolic events, demonstrating that squamous histology is essential for necitumumab benefit. BLA 125463 approved November 24, 2015. No OEL exists in any EHS framework for necitumumab; no platform references EGFR domain III KD 1.0 nM phage-display human library, IgG1 ADCC + no-α-Gal design, squamous histology selection, or SQUIRE landmark for this 168th mechanism class.

Phage-display fully human antibody generation and EGFR domain III binding: ImClone Systems (New York NY; founded 1984; acquired by Eli Lilly and Company 2008 [$6.5B]) used M13 filamentous phage-display technology with a large naïve human scFv library (diverse VH/VL combinations from human peripheral blood lymphocyte V-gene repertoire → cloned into scFv-pIII phage display plasmid → panning on recombinant EGFR ECD protein) to select IMC-11F8 — an anti-EGFR domain III scFv reformatted into fully human IgG1κ. No CDR grafting or humanization required (all V-gene sequences derived directly from human B-cell repertoire). IMC-11F8 EGFR binding: domain III competitive antagonist (overlapping EGF/TGF-α binding groove at EGFR AA287–333); KD ~1.0 nM (similar affinity to cetuximab); steric exclusion of EGF/TGF-α/AR/epiregulin → no EGFR Y992/Y1045/Y1068/Y1086/Y1148/Y1173 phosphorylation → no RAS/ERK + no PI3K/AKT activation. IgG1κ effector architecture: necitumumab Fc CH2 Leu234/Leu235/Trp231 → C1q binding (CDC) + FcγRIIIa CD16A binding (NK/macrophage ADCC) — unlike panitumumab (IgG2 no-ADCC). Fully human sequence advantage: no murine V-region sequences → no α-galactose (α-Gal) epitope on V-region Asn residues (IgE anti-Gal sensitization from tick bite Amblyomma americanum in southeastern US → cross-reactive to cetuximab Fab α-Gal glycan → Grade 3-4 infusion reaction up to 22% in southeastern US vs 1-3% elsewhere — necitumumab lacks this risk entirely). Squamous NSCLC histology-dependence: EGFR overexpression/amplification is more common in squamous (~80% EGFR 3+/FISH amplified) vs non-squamous (~25%); squamous NSCLC lacks KRAS mutations (which preclude EGFR antibody benefit in mCRC); pemetrexed (thymidylate synthase inhibitor) has negative interaction with EGFR blockade in non-squamous (INSPIRE: necitumumab + pemetrexed + cisplatin → PFS HR 1.01, OS HR 1.01; excess Grade 3-4 VTE 9% vs 5%) — histology-restricted approval unprecedented for EGFR antibody class. SQUIRE (Thatcher NEJM 2015; NCT00981058): n=1093; 1L squamous NSCLC (histologically confirmed); necitumumab 800 mg flat IV D1+D8 + gemcitabine 1250 mg/m² IV D1+D8 + cisplatin 75 mg/m² IV D1 Q3W (≤6 cycles then necitumumab maintenance until PD/toxicity) vs GC alone; primary endpoint OS: mOS 11.5 vs 9.9 mo (HR 0.84; 95%CI 0.74–0.96; p=0.0129); mPFS 5.7 vs 5.5 mo (HR 0.85; 95%CI 0.74–0.98; p=0.0205); ORR 31% vs 29%. BLA 125463 November 24 2015. No EHS platform recognizes necitumumab CAS 906805-06-9, EGFR domain III phage-display human library, IgG1 ADCC + CDC squamous-restricted mechanism, IMC-11F8 clone, or SQUIRE BLA 125463 for this 168th mechanism class.

EGFR Domain III Phage-Display Fully Human IgG1 + Squamous NSCLC Histology Restriction + INSPIRE Negative Non-Squamous Signal

Necitumumab (MW ~148 kDa fully human IgG1κ; CAS 906805-06-9; IV infusion 800 mg flat D1+D8 of Q3W cycle over 60 min; Cmax ~184 µg/mL; t½ ~14.0 days; Vd ~3.6 L; CL ~6.3 mL/kg/day — moderate interpatient PK variability; no dose modification for EGFR mutation status [squamous NSCLC EGFR mutation rate ~1–3%]; flat dosing 800 mg regardless of body weight/BSA [population PK analysis supports flat dosing in squamous NSCLC patients]) uses fully human IgG1κ architecture derived directly from phage-display selection (IMC-11F8 scFv → full-length IgG1κ reformatting; VH derived from IGHV1-69 germline family; VL from IGKV3-11 germline — commonly selected anti-EGFR V-gene germlines in human antibody libraries). IMC-11F8 → necitumumab: EGFR domain III binding (EGF-groove; Fab crystal structure coordinates analogous to cetuximab PDB 1YY9 but fully human VH/VL contact residues differing from murine-derived cetuximab VH/VL); no murine FR-encoded N-glycosylation sites (Asn residues in murine FR carry α-Gal glycan in murine cell expression → human cell expression of necitumumab [CHO] does not generate α-Gal → no anti-Gal IgE recognition → no tick-bite α-Gal sensitization pathway). IgG1κ Fc: Leu234/Leu235/Trp231 → C1q (CDC complement cascade → MAC); ASN297 Fc glycosylation [G0F/G1F/G2F] → FcγRIIIa CD16A (V158/F158 polymorphism; NK cells → ADCC). Squamous vs non-squamous NSCLC EGFR biology: squamous NSCLC has EGFR gene amplification (FISH ≥4 copies; ≥20% cells → ~25%); EGFR overexpression IHC 3+ (~80%); KRAS mutations absent (squamous NSCLC KRAS rate ~3% vs adenocarcinoma ~30%) → no RAS bypass mechanism; NKX2-1/SOX2 lineage (squamous) vs TTF-1/napsin lineage (adenocarcinoma) → fundamentally different biology explaining EGFR dependency differences. Non-squamous NSCLC: pemetrexed (TYMS inhibitor) in INSPIRE combination showed excess VTE (thromboembolic events Grade 3-4: 9.4% vs 4.7% — EGFR pathway modulates tissue factor + plasminogen activator inhibitor → pro-coagulant state amplified when combined with antimetabolite + platinum chemotherapy in non-squamous histology); INSPIRE (Paz-Ares 2015 Lancet Oncol): n=315; necitumumab + pem/cis vs pem/cis; mOS 11.3 vs 11.5 mo (HR 1.01; p=0.96) → no benefit → FDA label restricted to squamous only. BLA 125463 November 24 2015: 1L squamous NSCLC (histologically confirmed squamous cell carcinoma of the lung) + gemcitabine + cisplatin only. No EHS platform recognizes necitumumab CAS 906805-06-9, EGFR domain III phage-display human IgG1, IMC-11F8, squamous histology restriction, INSPIRE VTE signal, or SQUIRE BLA 125463 for this 168th mechanism class.

Surface 1 — Eli Lilly and Company Indianapolis IN BLA 125463 Holder AI

At Eli Lilly and Company Indianapolis IN ([Lilly Corporate Center, Indianapolis IN 46285; NYSE: LLY; BLA 125463 US HOLDER: necitumumab (Portrazza) for 1L squamous NSCLC + GC; PORTRAZZA DEVELOPER: via ImClone Systems acquisition [$6.5B cash October 2008]; ImClone (New York NY; founded 1984 by Samuel Waksal + Harlan Waksal) developed IMC-11F8 from phage-display library → necitumumab IgG1κ → Phase I-III SQUIRE; CORITY: CAS 906805-06-9 → null; necitumumab → null; Portrazza → null; IMC-11F8 → null; EGFR squamous NSCLC antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne necitumumab 0.0020 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00020 µg/m³; Cority: null; 46F regulatory affairs director 13yr]).

Surface 2 — Boehringer Ingelheim Pharma GmbH Biberach Germany Manufacturing AI

At Boehringer Ingelheim Pharma GmbH Biberach Germany ([Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany; Boehringer Ingelheim Biopharmaceuticals CDMO division; PORTRAZZA MANUFACTURING: upstream CHO suspension fed-batch bioreactors (necitumumab IgG1κ; protein A capture → low-pH viral inactivation → cation exchange → AEX polishing → UF/DF [10 mM acetate pH 5.0; 150 mM NaCl; 0.01% polysorbate 80] → fill/finish 800 mg/50 mL single-use vials); BIOSAFETY: necitumumab NIOSH HD Cat 1 → closed handling protocols; BI BIOPHARMACEUTICALS BIBERACH: largest BI manufacturing site; also manufactures nintedanib (OFEV; tyrosine kinase inhibitor BI 1120883); VELOCITYEHS: CAS 906805-06-9 → null; necitumumab → null; Portrazza → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne necitumumab 0.0014 µg/m³; impinger + MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 43M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Dana-Farber Cancer Institute Boston MA Squamous NSCLC Treatment AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Ave, Boston MA 02215; NCI Comprehensive Cancer Center; Thoracic Oncology Program; SQUAMOUS NSCLC TREATMENT SITE; PORTRAZZA + GEMCITABINE/CISPLATIN ADMINISTRATION: necitumumab 800 mg IV flat D1+D8 (over 60 min; premedicate diphenhydramine 50 mg IV if Grade 1-2 prior infusion reaction) + gemcitabine 1250 mg/m² IV D1+D8 + cisplatin 75 mg/m² IV D1; Q3W × ≤6 cycles then necitumumab maintenance; HISTOLOGY CONFIRMATION: squamous cell carcinoma of lung by IHC [p40/p63/CK5/6] required before Portrazza; CARDIOPULMONARY MONITORING: necitumumab hypomagnesemia (Grade 3-4: ~9%; mg supplementation protocol); NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 906805-06-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; necitumumab absent; Portrazza absent; IMC-11F8 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne necitumumab 0.0010 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL — no action"; 39F thoracic oncology pharmacist 10yr]).

Integrating Glyphward into Necitumumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every necitumumab CAS 906805-06-9 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + EGFR domain III absent + fully human IgG1 no-α-Gal absent + BLA 125463 2015 absent [10 pts]; FIRST fully human EGFR IgG1 antibody ever (168th class) + FIRST EGFR antibody ever approved for squamous NSCLC + IMC-11F8 phage-display fully human library [5 pts]; Eli Lilly Indianapolis + Boehringer Ingelheim Biberach + Dana-Farber Boston [3 pts]; FIRST phage-display human library anti-EGFR IgG1; FIRST squamous-histology-restricted EGFR antibody; FIRST EGFR antibody with no-α-Gal infusion reaction risk in IgG1 format [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_necitumumab(cas: str, reading_ugm3: float) -> dict:
    """Scan necitumumab with EGFR IgG1 squamous NSCLC phage-display human context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "906805-06-9"
                "reading_ugm3": reading_ugm3,
                "context": "egfr_fully_human_igg1_squamous_nsclc_168th_class_first_phage_display_egfr_bla125463"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, egfr_domain_iii,
    #                    fully_human_igg1, squamous_nsclc,
    #                    phage_display, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_necitumumab("906805-06-9", 0.0020))
    print(r)
    # {'hd_category': 1, 'egfr_domain_iii': True,
    #  'fully_human_igg1': True, 'squamous_nsclc': True,
    #  'phage_display': True, 'h360_flag': True}